[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 289,581,152
  • Shares Outstanding, K 1,908,152
  • Annual Sales, $ 56,674 M
  • Annual Income, $ 13,984 M
  • EBIT $ 17,216 M
  • EBITDA $ 22,491 M
  • 60-Month Beta 0.46
  • Price/Sales 5.26
  • Price/Cash Flow 14.01
  • Price/Book 7.37

Options Overview Details

View History
  • Implied Volatility 22.68% (-0.99%)
  • Historical Volatility 20.16%
  • IV Percentile 57%
  • IV Rank 46.73%
  • IV High 28.53% on 02/03/26
  • IV Low 17.55% on 11/06/25
  • Expected Move (DTE 27) 6.89 (4.52%)
  • Put/Call Vol Ratio 1.20
  • Today's Volume 284
  • Volume Avg (30-Day) 1,889
  • Put/Call OI Ratio 2.61
  • Today's Open Interest 81,491
  • Open Int (30-Day) 73,848
  • Expected Range 145.41 to 159.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.21
  • Number of Estimates 5
  • High Estimate $2.34
  • Low Estimate $2.11
  • Prior Year $2.42
  • Growth Rate Est. (year over year) -8.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
142.25 +6.90%
on 04/29/26
152.53 -0.31%
on 05/22/26
+4.74 (+3.22%)
since 04/22/26
3-Month
142.25 +6.90%
on 04/29/26
170.46 -10.79%
on 02/27/26
-10.61 (-6.52%)
since 02/20/26
52-Week
111.06 +36.92%
on 05/29/25
170.46 -10.79%
on 02/27/26
+39.56 (+35.16%)
since 05/22/25

Most Recent Stories

More News
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

NVDA : 216.62 (-1.32%)
GENB : 14.90 (+6.58%)
NVS : 152.54 (+0.51%)
AMGN : 339.14 (+0.51%)
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

SSNLF : 140.0000 (unch)
BABA : 130.10 (-1.04%)
AZN : 188.35 (-0.74%)
VXUS : 84.81 (+0.27%)
NVS : 152.54 (+0.51%)
TME : 8.83 (-3.50%)
TSM : 406.84 (-0.08%)
IXUS : 95.39 (+0.27%)
Amgen Expands Puerto Rico Biologics Facility With Additional $300M Investment Amid Tariff Pressure

Amgen ($AMGN) is investing an additional $300 million to expand its biologics manufacturing facility in Puerto Rico, bringing its recent commitments to the site to nearly $1 billion as drugmakers increase...

NVS : 152.54 (+0.51%)
AMGN : 339.14 (+0.51%)
Can Novartis Prove Its Pipeline Is Real Enough to Weather the Patent Cliff?

Barchart Research What to Expect from NVS Earnings NVS Generated April 27, 2026 Current Price $144.19 EPS Estimate $$2.11 Consensus Rating Moderate Buy Average Move 2.66% Can Novartis Prove Its Pipeline...

NVS : 152.54 (+0.51%)
Housing Figures, Bank Rate in Vogue Next Week

Monday U.S. Featured Earnings Verizon Communications Inc (NYSE:VZ) (Q1) EPS of $1.22, ...

GOOGL : 385.62 (-0.53%)
AAPL : 309.57 (+1.50%)
VZ : 48.43 (+0.33%)
KO : 81.41 (+0.30%)
CVX : 190.57 (-0.23%)
NVS : 152.54 (+0.51%)
MSFT : 418.92 (-0.04%)
LIN : 517.01 (+0.49%)
MA : 499.70 (+0.02%)
V : 329.95 (-0.35%)
XOM : 154.37 (-0.59%)
LLY : 1,065.78 (+2.32%)
3 Low-Volatility ETFs for Peace of Mind in Turbulent Times

With uncertainty plaguing the market, investors might be more inclined than usual to seek out low-volatility alternatives. These ETFs take multiple approaches.

SHY : 82.09 (-0.06%)
JEPI : 56.33 (+0.45%)
LVHI.BZ : N/A (N/A)
SHEL : 85.69 (-0.53%)
NVS : 152.54 (+0.51%)
IEF : 93.80 (+0.03%)
Pharma Giant Novartis Buys Biotech Firm Excellergy For $2 Billion

Pharmaceutical giant Novartis (NVS) is purchasing privately held biotechnology firm Excellergy for $2 ...

NVS : 152.54 (+0.51%)
3 ETFs to Avoid as Oil Shock Hits Markets

With oil prices soaring near $100 per barrel, certain sectors are feeling more pain than others. Here are three ETFs to avoid amid oil's market roil.

LVMUY : 108.8050 (-2.16%)
TRIP : 9.91 (+0.10%)
TSLA : 430.07 (+2.92%)
SAP : 176.47 (+0.11%)
XLY : 119.68 (+0.83%)
JETS : 27.28 (+1.04%)
EXPE : 213.85 (-1.96%)
NVS : 152.54 (+0.51%)
VGK : 88.71 (-0.06%)
RHHBY : 53.4750 (+1.45%)
AMZN : 268.41 (-0.02%)
Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent...

NVS : 152.54 (+0.51%)
Looking to ‘Sell America’ Amid Fed Drama? Here’s 1 ETF to Buy.

'Sell America' fear is rising again, and this non-U.S. ETF could be a wise buy to stay diversified and invested globally while U.S. policy risks swirl.

BLK : 1,076.91 (+1.24%)
BABA : 130.10 (-1.04%)
DXY00 : 99.223 (-0.03%)
SIH26 : 69.545s (+2.77%)
GCG26 : 5,206.4s (+0.98%)
NVS : 152.54 (+0.51%)
RHHBY : 53.4750 (+1.45%)
HSBC : 92.40 (+0.38%)
TSM : 406.84 (-0.08%)
ASML : 1,644.69 (+3.31%)
$DXY : 99.22 (-0.04%)
AZN : 188.35 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 155.99
2nd Resistance Point 154.25
1st Resistance Point 153.01
Last Price 152.54
1st Support Level 150.03
2nd Support Level 148.29
3rd Support Level 147.05

See More

52-Week High 170.46
Last Price 152.54
Fibonacci 61.8% 147.77
Fibonacci 50% 140.76
Fibonacci 38.2% 133.75
52-Week Low 111.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.